Trial of universal flu vaccine against six strains

National Institutes of Health Clinical Center (NIH) American University in Bethesda, Maryland has opened enrollment Phase I trial a new one Universal influenza vaccine candidatefor six plants Viral.The trial, sponsored by the National Institute of Allergy and Infectious Diseases (Niaid), a division of the National Institutes of Health (NIH), will evaluate Safety Studying vaccines and their ability to cause immune response.

New clinical trial hopes to enroll people 24 healthy volunteersBetween the ages of 18 and 50, who will receive Two intramuscular injections Study of the FluMos-v2 vaccine candidate.These injections will be 16 weeks apart. Initially, participants will be included in the lowest dose group (60 micrograms of each vaccine). If no safety concerns are identified after at least three participants receive that dose, recruitment will begin with the highest dose group (180 micrograms of each vaccine).Study Group Program Registration 12 people per group dose.

period After 40 weeks After the first vaccination, participants will receive Follow-up calls and regular check-ins Track their responses to experimental vaccines.will be taken blood sample Any immune response to the vaccine candidate is measured during study visits.

The new clinical trial hopes to recruit 24 healthy volunteers aged 18 to 50, who will receive two intramuscular injections of the FluMos-v2 vaccine candidate.

An ideal universal flu vaccine could pass lower frequency once a year and Protect against multiple strains of bacteria flu virus. “With each new universal influenza vaccine candidate and clinical trial, we take another step toward this goal.”pointed out Dr Hugh AuchinclossNiaid Interim Director.

The flu vaccines currently available are Effective against specific strains of bacteria. Each year, vaccines are re-evaluated and changed to better match the flu strains expected to dominate in the upcoming season. Most seasonal flu vaccines are designed to train the immune system to defend against three to four different strains of common flu viruses. Therefore, getting the universal flu vaccine can prevent more influenza.

Vaccine candidates under investigation, FluMos-v2, designed by researchers at the Niaid Vaccine Research Center (VRC).It is a adapt The above-mentioned universal influenza vaccine candidate, FluMos-v1first began human testing in 2021 and is still in clinical trials.

Dr. Auchincloss: “The ideal universal influenza vaccine would be given less frequently than annually and would protect against multiple influenza strains”

FluMos-v2 is designed to induce antibodies against multiple different strains of influenza virus by displaying portions of the influenza virus hemagglutinin (HA) protein in a repeating pattern on a self-assembled nanoparticle structure. Exposure to these harmless viral protein fragments prepares the immune system to recognize and fight the real virus.when testing animalan experimental vaccine produced by strong antibody response.

Vaccine candidate FluMos-v1 shows HA from four influenza strains, FluMos-v2 shows Six HAs: four influenza A viruses and two influenza B viruses. Researchers expect this will further expand immunity in vaccine recipients, providing protection against a wider variety of influenza viruses.

Source link

Leave a Comment